Evidence map›Paper›PMID 32913031›Full record

ArticleJournal for immunotherapy of cancer2020

Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.

Maysaloun Merhi, Afsheen Raza, Varghese Philipose Inchakalody, Kodappully S Siveen, Deepak Kumar, Fairooz Sahir, Sarra Mestiri, Shereena Hydrose, Niloofar Allahverdi, Munir Jalis and 8 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Maysaloun MerhiMedical Oncology, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Afsheen RazaMedical Oncology, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Varghese Philipose InchakalodyMedical Oncology, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Kodappully S SiveenHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Deepak KumarComputational Biology, Carnegie Mellon University - Qatar Campus, Doha, Ad Dawhah, Qatar.
Fairooz SahirHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Sarra MestiriHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Shereena HydroseHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Niloofar AllahverdiHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Munir JalisHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Allan RelecomHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Lobna Al ZaidanHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Mohamed Sir Elkhatim HamidHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Mai MostafaHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Abdul Rehman Zar GulHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Shahab UddinHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Mohammed Al HomsiHamad Medical Corporation, Doha, Ad Dawhah, Qatar.
Said DermimeMedical Oncology, National Center for Cancer Care and Research, Doha, Qatar sdermime@hamad.qa.ORCID 0000-0002-5526-7496
Hamad Medical Corporation · QACarnegie Mellon University Qatar · QANational Center for Cancer Care and Research · QA

Funding

Medical Research Council 17118/17
6 · The paper itself

Abstract

Combined radioimmunotherapy is currently being investigated to treat patients with cancer. Anti-programmed cell death-1 (PD-1) immunotherapy offers the prospect of long-term disease control in solid tumors. Radiotherapy has the ability to promote immunogenic cell death leading to the release of tumor antigens, increasing infiltration and activation of T cells. New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a cancer-testis antigen expressed in 20% of advanced gastric cancers and known to induce humoral and cellular immune responses in patients with cancer. We report on the dynamic immune response to the NY-ESO-1 antigen and important immune-related biomarkers in a patient with metastatic gastric cancer treated with radiotherapy combined with anti-PD-1 pembrolizumab antibody.Our patient was an 81-year-old man diagnosed with locally advanced unresectable mismatch repair-deficient gastric cancer having progressed to a metastatic state under a second line of systemic treatment consisting of an anti-PD-1 pembrolizumab antibody. The patient was subsequently treated with local radiotherapy administered concomitantly with anti-PD-1, with a complete response on follow-up radiologic assessment. Disease control was sustained with no further therapy for a period of 12 months before relapse. We have identified an NY-ESO-1-specific interferon-γ (IFN-γ) secretion from the patients' T cells that was significantly increased at response (****p˂0.0001). A novel promiscuous immunogenic NY-ESO-1 peptide P39 (P

Indexed as

Aged, 80 and overBiomarkers, TumorCombined Modality TherapyHumansMaleStomach NeoplasmsT-Lymphocyte SubsetsBiomarkers, Tumorantigensbiomarkerscase reportsCD4-CD8 ratiocombined modality therapyneoplasmtumor

Identifiers

PMID32913031
PMCPMC7484873
OpenAlexW3083953818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.